Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
www.nordion.com
NORDION
Corporate Presentation
September 5, 2013
2
Caution on Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of appli...
3
About Nordion
Delivering quality products to our global
customers for more than 60 years, our product
portfolio includes...
4
A Global Company
APPROXIMATELY
450 EMPLOYEES
SUPPLY OVER
500 CUSTOMERS
AROUND
30 PRODUCTS
ACROSS MORE THAN
40 COUNTRIES
...
5
103.6 108.7 95.4
89.4
122.8
101.0
29.0
42.6
48.5
0
50
100
150
200
250
300
2010 2011 2012
2012 Financial Highlights
Reven...
6
47.5 46.1
39
13.4
38.3
29.4
9.1
12.7
14.1
0
20
40
60
80
100
120
2010 2011 2012
2012 Financial Highlights
Segment Earning...
7
Q3 2013 Results
32.1
36.5
22.0
24.0
13.0
11.1
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2012 2013
Q3 Q3
Segmented Reve...
8
F2013 Timeline
DEC 4
Provided
update on
arbitration-
related costs
by AECL
JAN 26
Filed amended
statement of
claim again...
9
Leading Products in Global Markets
POTENTIAL >
< PRIORITY >
STERILIZATION
TECHNOLOGIES
TARGETED
THERAPIES
ADVANTAGE >
Op...
10
Specialty Isotopes: Sterilization Technologies
• Gamma sterilization is focused on
the prevention of disease
• Co-60 is...
11
MARKET MIX PRODUCTS DRIVERS
80%
10%
• Stents
• Patches
• Tissue
• Regen medicine
+ Aging population
+ Enhance devices
+...
12
Specialty Isotopes: Medical Isotopes
• Medical isotopes are used to prevent, diagnose
and treat disease
• Main isotope ...
13
Medical Isotopes (Mo-99) Supply Chain
• Established, reliable facilities providing high-quality isotopes to global cust...
14
Nordion Environmental, Health,
and Safety (EH&S) Program
• Creating a workplace that enriches
the health and well-being...
15
Nordion Environmental, Health,
and Safety (EH&S) Program
• Implementing measures in the design and operation of all of
...
16
In the Community
Other Programs:
• Employee Giving Program - Nordion
makes donations to not-for-profit
organizations no...
17
The talented, dedicated and
resilient people that make
up Nordion share a single
purpose:
• Maintain a global leadershi...
www.nordion.com
Find out more at
www.nordion.com
Follow us at
http://twitter.com/NordionInc
Upcoming SlideShare
Loading in …5
×

Nordion Corporate Presentation

31,480 views

Published on

Nordion is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world.

  • Be the first to comment

  • Be the first to like this

Nordion Corporate Presentation

  1. 1. www.nordion.com NORDION Corporate Presentation September 5, 2013
  2. 2. 2 Caution on Forward Looking Statements This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that are not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect” and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate in the circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward- looking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and risk factors referred to in our 2012 Annual Information Form (AIF). We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
  3. 3. 3 About Nordion Delivering quality products to our global customers for more than 60 years, our product portfolio includes: • Sterilization Technologies • Medical Isotopes Nordion is a health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease.
  4. 4. 4 A Global Company APPROXIMATELY 450 EMPLOYEES SUPPLY OVER 500 CUSTOMERS AROUND 30 PRODUCTS ACROSS MORE THAN 40 COUNTRIES 68% UNITED STATES 18% ROW 10% EUROPE 4% CANADA F2012 REVENUES BY REGION - $244.8M* *Revenues and regional breakdown include Targeted Therapies business, which was divested in July 2013 to BTG plc.
  5. 5. 5 103.6 108.7 95.4 89.4 122.8 101.0 29.0 42.6 48.5 0 50 100 150 200 250 300 2010 2011 2012 2012 Financial Highlights Revenue Trend (US$ Millions) * In July 2013, Nordion divested its Targeted Therapies business to BTG plc ** Key supplier down for repairs for 10 months in F2010 Medical Isotopes** Targeted Therapies*Sterilization Technologies
  6. 6. 6 47.5 46.1 39 13.4 38.3 29.4 9.1 12.7 14.1 0 20 40 60 80 100 120 2010 2011 2012 2012 Financial Highlights Segment Earnings Trend (US$ Millions) Medical Isotopes** Targeted Therapies*Sterilization Technologies Excludes corporate segmented loss * In July 2013, Nordion divested its Targeted Therapies business to BTG plc ** Key supplier down for repairs for 10 months in F2010
  7. 7. 7 Q3 2013 Results 32.1 36.5 22.0 24.0 13.0 11.1 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 2012 2013 Q3 Q3 Segmented Revenue (US$ millions) Segmented Earnings* (US$ millions) 14.4 17.8 4.6 5.94.3 0.5 0 5 10 15 20 25 30 2012 2013 * Excludes corporate segmented loss ** In July 2013, Nordion divested its Targeted Therapies business to BTG plc Medical Isotopes Targeted Therapies**Sterilization Technologies
  8. 8. 8 F2013 Timeline DEC 4 Provided update on arbitration- related costs by AECL JAN 26 Filed amended statement of claim against AECL JAN 28 Appointed Grant Gardiner as SVP, General Counsel MAY 23 Entered into agreement to divest Targeted Therapies business to BTG JUL 15 Announced divestiture completion of Targeted Therapies business to BTG MAR 21 Settled claims with Dr. Reddy's Labs MAY 15 Signed contract manufacturing agreement with Navidea AUG 20 Reach settlement with AECL to resolve MAPLE lawsuits and arbitration costs Update – remove Sept 5
  9. 9. 9 Leading Products in Global Markets POTENTIAL > < PRIORITY > STERILIZATION TECHNOLOGIES TARGETED THERAPIES ADVANTAGE > Optimize Medical Isotopes business • Pursue long-term supply • Maintain customer relationships • Transition business to BTG plc • Maintain quality customer service and supplier relationships Maintain Sterilization business; selectively invest in growth: • Geographic expansion • New applications • Global leader in cobalt-60 • Significant barriers to entry • Solid cash flow and gross margins • Recurring revenue base • A global provider in processing, packaging, & delivery • Extensive regulatory expertise and logistics & distribution network Approximately 40% of single- use medical products worldwide are sterilized using gamma sterilization technologies Over 10,000 hospitals worldwide use radioisotopes in medical procedures with about 90% being for diagnosis. MEDICAL ISOTOPES DIVESTED BUSINESS GO-FORWARD BUSINESSES
  10. 10. 10 Specialty Isotopes: Sterilization Technologies • Gamma sterilization is focused on the prevention of disease • Co-60 is used to sterilize medical devices, instruments and supplies and food • Customers of Co-60 include contract sterilization service providers and medical device and product manufacturers • The Nordion Gamma Centre of Excellence is a world class applied research and specialty gamma processing facility to promote and expand the use of gamma globally • Nordion manufactures Co-60 irradiation sources, and designs, constructs and maintains commercial gamma sterilization systems
  11. 11. 11 MARKET MIX PRODUCTS DRIVERS 80% 10% • Stents • Patches • Tissue • Regen medicine + Aging population + Enhance devices + Leverage drugs + Stem cell research 10% Sterilization Market Segmentation MEDICAL & SURGICAL BIO-ACTIVE DEVICES FOOD SAFETY • Syringes • Catheters • Drapes, gowns • Sutures, gloves + Aging population + Min invasive surgery + Smaller devices + Material • Fruits & vegetables • Spices • Meat and poultry • Ready To Eat (RTE) + FDA labeling + USDA FEA + Food safety concerns 10% 80%
  12. 12. 12 Specialty Isotopes: Medical Isotopes • Medical isotopes are used to prevent, diagnose and treat disease • Main isotope supply sources are nuclear reactors and cyclotrons • Primary product is Mo-99, which decays for use in Technetium-99 (Tc-99m) generators, used in imaging to diagnose heart disease and cancers • Other Key Reactor Isotopes: – Xenon-133 (Xe-133), used in lung scans; – Iodine-131 (I-131), used to treat hyperthyroidism, thyroid cancer and non-Hodgkin’s lymphoma; – Iodine-125 (I-125), used to treat prostate cancer; • Key Cyclotron Isotopes: – Iodine-123 (I-123), used to diagnose thyroid disease; – Strontium-82 (Sr-82), used to manufacture rubidium-82 generators, which are used in imaging to diagnose heart disease – Thallium-201 (Tl-201), used to diagnose and assess risk of coronary artery heart disease; – Palladium-103 (Pd-103), used to treat prostate cancer; – Indium-111 (In-111) and Gallium-67 (Ga-67) (both used to diagnose infection and cancer) at our Vancouver facilities
  13. 13. 13 Medical Isotopes (Mo-99) Supply Chain • Established, reliable facilities providing high-quality isotopes to global customers • Specialty skills in operations, regulatory affairs and global logistics Irradiation of HEU targets to produce crude isotopes NUCLEAR REACTORS Purification of Mo-99 and distribution to global radiopharmaceutical manufacturers MEDICAL ISOTOPE PROCESSORS Tc-99m Generator manufacturing and distribution to radiopharmacies RADIOPHARMACEUTICAL MANUFACTURERS Unit dose compounding and distribution to hospital/departments RADIOPHARMACIES AND HOSPITALS Critical physiological diagnosis enabling informed therapeutic decisions PHYSICIANS AND PATIENTS
  14. 14. 14 Nordion Environmental, Health, and Safety (EH&S) Program • Creating a workplace that enriches the health and well-being of Nordion employees • Demonstrating Environmental, Health, and Safety (EH&S) regulatory excellence • Improving EH&S performance – continually • Managing EH&S with excellence
  15. 15. 15 Nordion Environmental, Health, and Safety (EH&S) Program • Implementing measures in the design and operation of all of our facilities to keep radiation dose received by workers and the public ALARA (as low as reasonably achievable) • Implementing an ISO 14001-based environmental management (EMS) system at our Ottawa site • Establishing EH&S objectives and targets annually to continually improve our performance • Maintaining - and building on - a comprehensive training program for employees and contractors • Engraining EH&S excellence into the Nordion culture • Investing in a world class approach to EH&S ISO 14001: 2004 certified Recipient of the Government of Canada 2007 ENERGY STAR ® Market Transformation Award Practitioner of LeanSigma, a methodology used to continually improve processes Recipient of an unprecedented ten-year license renewal from the Canadian Nuclear Safety Commission (CNSC)
  16. 16. 16 In the Community Other Programs: • Employee Giving Program - Nordion makes donations to not-for-profit organizations nominated by employees • Proud sponsor of the Gala for Research, an annual black-tie event to support the Ottawa Hospital Research Institute, the research arm of The Ottawa Hospital • Sponsor and key supporter of the University of Ottawa Heart Institute Telethon Ride the Rideau Title sponsor of Ride the Rideau since its inauguration in 2010, Nordion has helped to raise over $4.4 million for cancer research at The Ottawa Hospital Research Institute.
  17. 17. 17 The talented, dedicated and resilient people that make up Nordion share a single purpose: • Maintain a global leadership position in our key markets • Build value for shareholders through the execution of our strategic priorities • Be a trusted, world-class provider of healthcare products to our customers Business Outlook
  18. 18. www.nordion.com Find out more at www.nordion.com Follow us at http://twitter.com/NordionInc

×